Abstract 307P
Background
Lacrimal gland is an exocrine secretory gland located at the upper temporal fossa of the orbit. It is part of the tear-forming apparatus that constitutes an important orbital structure. However, data available about tumors possibly originating in this site are scarce. In this study, we aimed to spotlight on this rare type of malignancy using the using data from American National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program.
Methods
We used SEER*Stat version 8.3.4, Microsoft Excel, as well as SPSS IBM SPSS Statistics for Windows, Version 21.0. In SEER*Stat, we used the (Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2015 Sub (1973-2013 varying)) database. We included SEER 18 cases that were diagnosed after 2003 (2004+) in which the primary site was identified as (C69.5 – Lacrimal gland). Only cases with malignant behavior, known age, and those in the Research Database were included.
Results
A total of 491 cases were identified with a median age of 63. Females represented the majority of the analyzed cohort (n = 263, 53.6%). Lacrimal gland tumors were most common among the white race (n = 376, 76.6%). Age-adjusted Incidence rate was 0.6 per 1,000,000 with a median survival of 41 months, while 5-year relative survival was 88.4% (CI: 81.9% - 92.6%). The most common pathology of studied cases was Non-Hodgkin lymphoma (n = 254, 51.7%) (Table).Table:
307P Different pathological subtypes for lacrimal gland tumours
Pathological Subtype | N. | % |
---|---|---|
NHL-Mature B-Cell Lymphomas | 254 | 51.7 % |
Squamous Cell Neoplasms | 71 | 14.5 % |
Adenomas &Adenocarcinomas | 64 | 13.0 % |
Malignant Lymphomas, NOS Or Diffuse | 32 | 6.5 % |
Mucoepidermoid Neoplasms | 17 | 3.5 % |
Epithelial Neoplasms, NOS | 10 | 2.0 % |
Nevi Melanomas | 8 | 1.6 % |
Ductal & Lobular Neoplasms | 7 | 1.4 % |
Lymphoid Leukemias (C42.1) | 6 | 1.2 % |
Transitional Cell Papillomas & Carcinomas | 4 | 0.8 % |
Complex Mixed & Stromal Neoplasms | 4 | 0.8 % |
Myomatous Neoplasms | 3 | 0.6 % |
Basal Cell Neoplasms | 2 | 0.4 % |
Complex Epithelial Neoplasms | 2 | 0.4 % |
Plasma Cell Tumors | 2 | 0.4 % |
Unspecified Neoplasms | 1 | 0.2 % |
Cystic, Mucinous & Serous Neoplasms | 1 | 0.2 % |
Fibromatous Neoplasms | 1 | 0.2 % |
Hodgkin Lymphomas | 1 | 0.2 % |
Nhl-Mature T & Nk-Cell Lymphomas | 1 | 0.2 % |
Conclusions
Lacrimal gland tumors are extremely rare with incidence rate of 0.6 per million. These tumors are more likely to occur in old age, females, white race. 5-years relative survival is 88.4% with a median survival of 41 months.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract